
CervoMed Inc (CRVO) Stock Forecast & Price Target
CervoMed Inc (CRVO) Analyst Ratings
Bulls say
CervoMed is set to release near-term, near-term lease, a clinical-phase biotechnology company developing Neflamapimod, a product designed to improve synaptic function and potentially treat neurodegenerative disorders like non-fluent primary progressive aphasia (nfvPPA). Early data suggests that Neflamapimod may have a positive impact on patients with low plasma pTau181 levels, providing hope for its future potential in treating age-related neurological conditions.
Bears say
CervoMed is a clinical-stage biotechnology company with a negative outlook due to its low product revenue and high risk factors, such as slow market uptake and potential dilution risk. Despite positive clinical data for their product candidate, Neflamapimod, in the treatment of age-related neurologic disorders, the company's valuation based on a DCF analysis is only $640M, translating to a price target of $25 per share. Furthermore, the company's plans for a pivotal trial in DLB have not yet come to fruition, and they still rely heavily on partnerships for drug development and funding.
This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.
CervoMed Inc (CRVO) Analyst Forecast & Price Prediction
Start investing in CervoMed Inc (CRVO)
Order type
Buy in
Order amount
Est. shares
0 shares